Dragon Pharma’s Methylene Blue (Methylthioninium Chloride) is a newly introduced oral compound designed with a focus on precision dosing and product quality. As part of the Dragon Pharma lineup, this product is manufactured to meet consistent standards from the very first production batches.
Below is the first available independent lab test verifying the potency of Methylene Blue 50 mg tablets, conducted by a trusted third-party laboratory.
Latest Lab Result (2026)
Janoshik Lab Report – 2026-03-23
- Product: Methylene Blue
- Active Substance: Methylthioninium Chloride
- Labeled Dosage: 50 mg/tablet
- Result: 53.72 mg/tablet
- Laboratory: Janoshik
This initial lab test shows a measured concentration of 53.72 mg per tablet, which is slightly above the labeled 50 mg dosage. This result indicates accurate formulation with a small positive variance, a common characteristic in pharmaceutical manufacturing to ensure minimum label compliance.
Potency Analysis
The first independent lab test of Dragon Pharma Methylene Blue confirms that the product delivers a dosage slightly above the labeled 50 mg per tablet.
- Labeled dosage: 50 mg
- Tested dosage: 53.72 mg
- Deviation: +3.72 mg (~7.4%)
- Consistency status: Initial batch verified
This level of accuracy suggests careful formulation and provides a strong baseline for future batch consistency as additional lab reports become available.
About Methylene Blue (Methylthioninium Chloride)
Methylene Blue, also known as Methylthioninium Chloride, is a well-known compound with a long history of use in medical and laboratory settings. In controlled formulations, it is valued for its stability and precise dosing requirements.
For tablet-based products, accurate dosing is particularly important, and independent lab verification helps confirm that each batch meets expected standards.
Conclusion
The first available lab test for Dragon Pharma Methylene Blue (50 mg tablets) confirms a measured dosage of 53.72 mg per tablet, slightly exceeding the labeled amount. This result supports accurate formulation and establishes a positive starting point for product consistency.
As a newly released product, additional lab reports over time will provide a broader view of batch-to-batch consistency. However, this initial test from Janoshik offers early verification of potency and quality.
Frequently Asked Questions
Yes, the first independent lab test shows a measured dosage of 53.72 mg per tablet, slightly above the labeled 50 mg.
The available lab report was conducted by Janoshik, a recognized independent testing laboratory.
Since this is a newly released product, only one lab test is currently available. Future reports will help confirm long-term batch consistency.
Yes, the available test result shows a slightly higher concentration than labeled, which is within expected manufacturing variance.
